Cover Image
Market Research Report

Europe Drug Delivery Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 932719
Published Content info 140 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Drug Delivery Market - Industry Trends and Forecast to 2027
Published: March 1, 2020 Content info: 140 Pages
Description

Europe drug delivery market is projected to register a substantial growth in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Europe Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End User (Hospitals, Community Healthcare, Home Healthcare, Clinics, Others), Distribution Channel (Hospital Pharmacies, Pharmacy Stores, Direct Tenders, Online Pharmacy), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Rest of Europe), Market Trends and Forecast to 2027.

Some of the major factors contributing to the growth of the Europe drug delivery market are:

  • Increasing awareness about diagnosis and treatment
  • Technological development

Market Players

The Key Market Players for Europe drug delivery market are listed below:

  • Johnson & Johnson services, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Pfizer Inc.
  • 3M
  • Antares Pharma
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
  • Nemera
  • Sanofi
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF EUROPE DRUG DELIVERY MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCTS LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

  • 5.1 DRIVERS
    • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON CHRONIC DISEASE
    • 5.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS
    • 5.1.3 TECHNOLOGICAL DEVELOPMENT
    • 5.1.4 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
    • 5.1.5 RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
  • 5.2 RESTRAINTS
    • 5.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
    • 5.2.2 HIGH COSTS OF DRUGS
    • 5.2.3 STRINGENT REGULATORY SCENARIO
    • 5.2.4 PRODUCT RECALLS

  • 5.3 OPPORTUNITIES
    • 5.3.1 RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
    • 5.3.2 THERAPEUTIC ADVANCEMENTS
    • 5.3.3 TREND OF MERGER AND ACQUISITIONS AND COLLABORATIONS
    • 5.3.4 FOCUS ON PATIENTS' NEEDS
    • 5.3.5 DEVELOPING AND NEW EMERGING REVENUE POCKETS
  • 5.4 CHALLENGES
    • 5.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
    • 5.4.2 PATENT EXPIRY AND PATENT CLIFF
    • 5.4.3 ALTERNATIVES TO DRUG DELIVERY

6 EUROPE DRUG DELIVERY MARKET, BY PRODUCT TYPE

  • 6.1 OVERVIEW
  • 6.2 ORAL DRUG DELIVERY
    • 6.2.1 BY FORM
      • 6.2.1.1 SOLID ORAL DRUGS
        • 6.2.1.1.1 TABLETS
        • 6.2.1.1.2 CAPSULES
        • 6.2.1.1.3 PILLS
        • 6.2.1.1.4 POWDERS
      • 6.2.1.2 LIQUID ORAL DRUGS
        • 6.2.1.2.1 SYRUPS
        • 6.2.1.2.2 SOLUTIONS
      • 6.2.1.3 semi solid oral drugs
        • 6.2.1.3.1 GELS
        • 6.2.1.3.2 EMULSIONS
        • 6.2.1.3.3 ELIXIRS
  • 6.3 INJECTABLE DRUG DELIVERY
    • 6.3.1 INJECTABLE DRUG DELIVERY DEVICES
      • 6.3.1.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
        • 6.3.1.1.1 BY MATERIAL TYPE
        • 6.3.1.1.1.1 GLASS
        • 6.3.1.1.1.2 PLASTIC
        • 6.3.1.1.2 BY PRODUCT TYPE
        • 6.3.1.1.2.1 FILLABLE
        • 6.3.1.1.2.2 PRE-FILLED
        • 6.3.1.1.3 BY USABILITY
        • 6.3.1.1.3.1 REUSABLE SYRINGES
        • 6.3.1.1.3.2 DISPOSABLE SYRINGES

      • 6.3.1.2 SELF-INJECTION DRUG DELIVERY
        • 6.3.1.2.1 NEEDLE FREE INJECTORS
        • 6.3.1.2.2 WEARABLE INJECTORS
        • 6.3.1.2.3 PEN INJECTOR
        • 6.3.1.2.4 AUTO INJECTORS
        • 6.3.1.2.5 OTHERS
    • 6.3.2 INJECTABLE DRUG DELIVERY FORMULATIONS
      • 6.3.2.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
      • 6.3.2.2 NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.3 LONG ACTING INJECTION FORMULATIONS
  • 6.4 OPHTHALMIC DRUG DELIVERY
      • 6.4.1.1 OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.1 LIQUID OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.1.1 SOLUTIONS
        • 6.4.1.1.1.2 SUSPENSIONS
        • 6.4.1.1.2 SEMI SOLID OCULAR DRUG DELIVERY FORMULATIONS
        • 6.4.1.1.2.1 GELS
        • 6.4.1.1.2.2 OINTMENTS
      • 6.4.1.2 OCULAR DRUG DELIVERY DEVICES
        • 6.4.1.2.1.1 DRUG COATED CONTACT LENSES
        • 6.4.1.2.1.2 OCULAR INSERTS
  • 6.5 NASAL DRUG DELIVERY
    • 6.5.1 NASAL DROPS
    • 6.5.2 NASAL SPRAYS
    • 6.5.3 NASAL POWDERS
    • 6.5.4 NASAL GELS
  • 6.6 TOPICAL DRUG DELIVERY
    • 6.6.1 TRANSDERMAL DRUG DELIVERY DEVICES
      • 6.6.1.1 TRANSDERMAL PATCHES
      • 6.6.1.2 TRANSDERMAL GELS
    • 6.6.2 TRANSDERMAL DRUG DELIVERY FORMULATIONS
      • 6.6.2.1 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.1.1 SUSPENSIONS
        • 6.6.2.1.2 SOLUTIONS
      • 6.6.2.2 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.2.1 OINTMENTS
        • 6.6.2.2.2 CREAMS
        • 6.6.2.2.3 LOTIONS
        • 6.6.2.2.4 GELS
        • 6.6.2.2.5 PASTES
      • 6.6.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
        • 6.6.2.3.1 POWDER
        • 6.6.2.3.2 SUPPOSITORS
  • 6.7 IMPLANTABLE DRUG DELIVERY
    • 6.7.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
    • 6.7.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
  • 6.8 TRANSMUCOSAL DRUG DELIVERY
    • 6.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
      • 6.8.1.1 BUCCAL DRUG DELIVERY
      • 6.8.1.2 SUBLINGUAL DRUG DELIVERY
    • 6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
      • 6.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
      • 6.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
  • 6.9 PULMONARY DRUG DELIVERY
    • 6.9.1 METERED DOSE INHALERS (MDI)
    • 6.9.2 DRY POWDER INHALERS (DPI)
    • 6.9.3 NEBULIZERS
      • 6.9.3.1 JET NEBULIZERS
      • 6.9.3.2 ULTRASONIC NEBULIZERS
      • 6.9.3.3 SOFT MIST NEBULIZERS

7 EUROPE DRUG DELIVERY MARKET, BY END USER

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.3 HOME HEALTHCARE
  • 7.4 CLINICS
  • 7.5 COMMUNITY HEALTHCARE
  • 7.6 OTHERS

8 EUROPE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

  • 8.1 OVERVIEW
  • 8.2 DIRECT TENDERS
  • 8.3 HOSPITAL PHARMACIES
  • 8.4 PHARMACY STORES
  • 8.5 ONLINE PHARMACY

9 EUROPE DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 9.1 EUROPE
    • 9.1.1 GERMANY
    • 9.1.2 FRANCE
    • 9.1.3 ITALY
    • 9.1.4 U.K.
    • 9.1.5 SWITZERLAND
    • 9.1.6 SPAIN
    • 9.1.7 NETHERLANDS
    • 9.1.8 RUSSIA
    • 9.1.9 TURKEY
    • 9.1.10 BELGIUM
    • 9.1.11 REST OF EUROPE

10 EUROPE DRUG DELIVERY MARKET, COMPANY LANDSCAPE

  • 10.1 COMPANY SHARE ANALYSIS: EUROPE

11 COMPANY PROFILES

  • 11.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1 COMPANY SNAPSHOT
    • 11.1.2 REVENUE ANALYSIS
    • 11.1.3 COMPANY SHARE ANALYSIS
    • 11.1.4 PRODUCT PORTFOLIO
    • 11.1.5 RECENT DEVELOPMENTS
  • 11.2 NOVARTIS AG
    • 11.2.1 COMPANY SNAPSHOT
    • 11.2.2 REVENUE ANALYSIS
    • 11.2.3 COMPANY SHARE ANALYSIS
    • 11.2.4 PRODUCT PORTFOLIO
    • 11.2.5 RECENT DEVELOPMENTS
  • 11.3 F. HOFFMANN-LA ROCHE LTD
    • 11.3.1 COMPANY SNAPSHOT
    • 11.3.2 REVENUE ANALYSIS
    • 11.3.3 COMPANY SHARE ANALYSIS
    • 11.3.4 PRODUCT PORTFOLIO
    • 11.3.5 RECENT DEVELOPMENTS

  • 11.4 BAYER AG
    • 11.4.1 COMPANY SNAPSHOT
    • 11.4.2 REVENUE ANALYSIS
    • 11.4.3 COMPANY SHARE ANALYSIS
    • 11.4.4 PRODUCT PORTFOLIO
    • 11.4.5 RECENT DEVELOPMENTS
  • 11.5 PFIZER INC.
    • 11.5.1 COMPANY SNAPSHOT
    • 11.5.2 REVENUE ANALYSIS
    • 11.5.3 COMPANY SHARE ANALYSIS
    • 11.5.4 BRAND PORTFOLIO
    • 11.5.5 RECENT DEVELOPMENTS
  • 11.6 3M
    • 11.6.1 COMPANY SNAPSHOT
    • 11.6.2 REVENUE ANALYSIS
    • 11.6.3 PRODUCT PORTFOLIO
    • 11.6.4 RECENT DEVELOPMENTS
  • 11.7 ANTARES PHARMA
    • 11.7.1 COMPANY SNAPSHOT
    • 11.7.2 REVENUE ANALYSIS
    • 11.7.3 PRODUCT PORTFOLIO
    • 11.7.4 RECENT DEVELOPMENTS
  • 11.8 GLAXOSMITHKLINE PLC
    • 11.8.1 COMPANY SNAPSHOT
    • 11.8.2 REVENUE ANALYSIS
    • 11.8.3 PRODUCT PORTFOLIO
    • 11.8.4 RECENT DEVELOPMENTS
  • 11.9 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 11.9.1 COMPANY SNAPSHOT
    • 11.9.2 REVENUE ANALYSIS
    • 11.9.3 PRODUCT PORTFOLIO
    • 11.9.4 RECENT DEVELOPMENTS
  • 11.10 NEMERA
    • 11.10.1 COMPANY SNAPSHOT
    • 11.10.2 PRODUCT PORTFOLIO
    • 11.10.3 RECENT DEVELOPMENTS

  • 11.11 SANOFI
    • 11.11.1 COMPANY SNAPSHOT
    • 11.11.2 REVENUE ANALYSIS
    • 11.11.3 PRODUCT PORTFOLIO
    • 11.11.4 RECENT DEVELOPMENTS

12 QUESTIONNAIRE

13 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 EUROPE DRUG DELIVERY MARKET: SEGMENTATION
  • FIGURE 2 EUROPE DRUG DELIVERY MARKET: DATA TRIANGULATION
  • FIGURE 3 EUROPE DRUG DELIVERY MARKET: DROC ANALYSIS
  • FIGURE 4 EUROPE DRUG DELIVERY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 EUROPE DRUG DELIVERY MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 EUROPE DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 EUROPE DRUG DELIVERY MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 EUROPE DRUG DELIVERY MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 9 EUROPE DRUG DELIVERY MARKET: SEGMENTATION
  • FIGURE 10 RISING PREVALENCE OF CHRONIC DISEASES AND NON CHRONIC DISEASES AND GROWTH IN THE DEVELOPMENT OF BIOLOGICS ARE EXPECTED TO BE KEY DRIVING FACTORS IN THE EUROPE DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 11 ORAL DRUG DELIVERY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DRUG DELIVERY MARKET IN 2020 & 2027
  • FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE DRUG DELIVERY MARKET
  • FIGURE 13 EUROPE DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019
  • FIGURE 14 EUROPE DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019-2027 (USD BILLION)
  • FIGURE 15 EUROPE DRUG DELIVERY MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
  • FIGURE 16 EUROPE DRUG DELIVERY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
  • FIGURE 17 EUROPE DRUG DELIVERY MARKET: BY END USER, 2019
  • FIGURE 18 EUROPE DRUG DELIVERY MARKET: BY END USER, 2019-2027 (USD BILLION)
  • FIGURE 19 EUROPE DRUG DELIVERY MARKET: BY END USER, CAGR (2020-2027)
  • FIGURE 20 EUROPE DRUG DELIVERY MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 21 EUROPE DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019
  • FIGURE 22 EUROPE DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
  • FIGURE 23 EUROPE DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
  • FIGURE 24 EUROPE DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 25 EUROPE DRUG DELIVERY MARKET: SNAPSHOT (2019)
  • FIGURE 26 EUROPE DRUG DELIVERY MARKET: BY COUNTRY (2019)
  • FIGURE 27 EUROPE DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027)
  • FIGURE 28 EUROPE DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027)
  • FIGURE 29 EUROPE DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027)
  • FIGURE 30 EUROPE DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%)
Back to Top